# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Reni Benjamin maintains BioAtla (NASDAQ:BCAB) with a Market Outperform and lowers the price target fr...
HC Wainwright & Co. analyst Arthur He reiterates BioAtla (NASDAQ:BCAB) with a Buy and maintains $7 price target.
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11...
JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $12 price target.
HC Wainwright & Co. analyst Arthur He maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $10 to...
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.79) by 29...